Melissa K. Frey, MD

Gynecologic Oncology

Locations and Appointments

Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

*Indicates this doctor is no longer accepting new patients with this insurance plan.

  • HMO
  • Medicare
  • PPO
  • EPO/POS
  • *CHP
  • Blue Access
  • Blue Connection
  • EPO
  • HMO
  • Mediblue (Senior)
  • PPO
  • CBP
  • *Medicaid
  • Medicare
  • Freedom
  • Liberty
  • Medicare Advantage
  • Metro/Core/Charter
  • *Community Plan
  • Medicare
  • HMO
  • Medicare
Personal Statement

"I am dedicated to the surgical and medical management of women’s cancer and also committed to advancing clinical and translational research in this field, with a focus on cancer genetics including hereditary breast and ovarian cancer (BRCA1/2) and Lynch syndrome."

Biographical Info

Dr. Melissa Frey is an Associate Professor of Obstetrics and Gynecology in the Division of Gynecologic Oncology and the Director of the Genetics and Personalized Cancer Prevention Program at Weill Cornell Medicine. Dr. Frey graduated magna cum laude and Phi Beta Kappa from Duke University and earned her medical degree from Weill Cornell Medical College, graduating with honors in research. She completed her residency in Obstetrics and Gynecology at Weill Cornell Medicine / NewYork-Presbyterian, where she served as the Chief Resident. She subsequently completed her fellowship in gynecologic oncology at New York University Langone Medical Center and received a master's degree in Clinical and Translational Investigation at Weill Cornell Medicine Graduate School of Medical Sciences.

Dr. Frey provides care for all aspects of gynecologic oncology, including surgical management and chemotherapy for gynecologic cancer.  Dr. Frey specializes in the management of individuals with hereditary cancer syndromes (e.g., BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, and Lynch syndrome). 

Dr. Frey’s research focuses on cancer genetics and healthcare delivery. She has presented her research at national and international meetings and has more than 100 publications in peer-reviewed scientific journals. Dr. Frey is the Principal Investigator on NIH-funded clinical trials evaluating cascade genetic testing and health information technology for cancer risk assessment in diverse patient populations. 

Dr. Frey has received numerous awards for her clinical excellence, surgical expertise, and medical research, including the American Board of Obstetrics and Gynecology / American Association of Obstetricians and Gynecologists Foundation Scholar Award, Siegel Family Faculty Development Prize, Sarnoff Research Foundation Fellowship, Alan von Kreuter Cancer Research Prize and several resident and medical student faculty teaching awards.

Board Certifications
American Board of Obstetrics & Gynecology
American Board of Obstetrics & Gynecology (Gynecologic Oncology)
Clinical Expertise
Cervical Cancer
Chemotherapy
Endometrial Cancer
Laparoscopic Surgery
Minimally Invasive Surgery
Ovarian Cancer
Robotic Surgery
Uterine Cancer
Vaginal Cancer
Vulvar Cancer
Languages
English
Education 
  • M.S.
    Weill Graduate School of Medical Sciences of Cornell University
    2022
  • M.D.
    Weill Cornell Medical College, Cornell University
    2009
  • B.A.
    Duke University
    2004
Appointments 
  • Associate Attending Obstetrician and Gynecologist
    NewYork-Presbyterian Hospital
  • Associate Professor of Obstetrics and Gynecology
    Weill Cornell Medical College, Cornell University
Videos

How Research Helps Us Treat Gynecologic Cancers | Dr. Melissa K. Frey | Weill Cornell Medicine

From the field to the exam room | Dr. Melissa Frey | Weill Cornell Medicine

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

Ownership: 
WndrHLTH